<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01794117</url>
  </required_header>
  <id_info>
    <org_study_id>130071</org_study_id>
    <secondary_id>13-AR-0071</secondary_id>
    <nct_id>NCT01794117</nct_id>
  </id_info>
  <brief_title>Anakinra for Inflammatory Pustular Skin Diseases</brief_title>
  <official_title>A Phase 2 Study of Anakinra in Inflammatory Pustular Dermatoses: Evaluation of Therapeutic Efficacy and Validation of Pathogenic Mechanisms</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background:&#xD;
&#xD;
        -  Inflammatory pustular skin diseases are a type of autoinflammatory disease in which the&#xD;
           immune system attacks the bodys tissues. These diseases cause painful and itchy skin&#xD;
           rashes, eye and mouth irritation, joint pain and fever. Several drugs for treating these&#xD;
           diseases suppress the immune system. However, they can cause severe side effects when&#xD;
           taken over a long period of time.&#xD;
&#xD;
        -  Interleukin 1 (IL-1) is a small protein that may be important in causing the&#xD;
           inflammation seen in pustular skin disease. Anakinra is a drug that works by blocking&#xD;
           IL-1. It has been effective in treating some inflammatory conditions such as rheumatoid&#xD;
           arthritis. However, anakinra has not been studied for use in patients with pustular skin&#xD;
           disease. Researchers want to see whether anakinra will be effective in treating pustular&#xD;
           skin disease.&#xD;
&#xD;
      Objectives:&#xD;
&#xD;
      - To see if anakinra can be used to treat inflammatory pustular skin disease.&#xD;
&#xD;
      Eligibility:&#xD;
&#xD;
      - Individuals at least 18 years of age who have inflammatory pustular skin disease.&#xD;
&#xD;
      Design:&#xD;
&#xD;
        -  Participants will be screened with a physical exam and medical history. Their disease&#xD;
           will be evaluated with blood tests, urine tests and imaging studies. Skin biopsies may&#xD;
           also be collected.&#xD;
&#xD;
        -  Participants will have an initial visit to receive the first dose of anakinra. They will&#xD;
           be shown how to give themselves daily injections of anakinra.&#xD;
&#xD;
        -  Participants will take anakinra for up to 12 weeks as long as there are no severe side&#xD;
           effects. During this time, they will keep a study diary to record the severity of any&#xD;
           rashes, pustules, itching, fevers, and skin or joint pain. They will bring this diary to&#xD;
           their study visits.&#xD;
&#xD;
        -  Participants will have study visits at weeks 4, 8 and 12. Treatment will be monitored at&#xD;
           these visits with blood tests, urine tests and physical exams. Depending on the effects&#xD;
           of the treatment, participants may have the dose of anakinra increased or decreased.&#xD;
&#xD;
        -  Participants will have a final study visit 4 weeks after they stop taking anakinra.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background:&#xD;
&#xD;
        -  Inflammatory disorders that present with neutrophilic pustular skin lesions, including&#xD;
           generalized pustular psoriasis, are characterized by severe cutaneous manifestations,&#xD;
           generalized inflammation and significant morbidity.&#xD;
&#xD;
        -  Recent studies in patients with phenotypically similar pustular diseases have identified&#xD;
           two monogenic forms of neutrophilic pustular psoriasis implicating interleukin (IL)-1 in&#xD;
           disease pathogenesis.&#xD;
&#xD;
             -  Deficiency of the Interleukin 1 (IL-1) receptor antagonist (IL1RN, DIRA) is an&#xD;
                autosomal recessive condition characterized by severe generalized pustular&#xD;
                eruptions in the neonatal period, osteopenia, lytic bone lesions, joint pain,&#xD;
                respiratory insufficiency, thrombosis, elevated acute phase reactants and&#xD;
                significant mortality. Patients with this condition have responded rapidly to IL-1&#xD;
                receptor antagonist, anakinra.&#xD;
&#xD;
             -  Deficiency of IL-36 receptor antagonist (IL-36RN/IL1F5, DITRA) is an autosomal&#xD;
                recessive condition with episodic widespread pustular skin lesions, fevers and&#xD;
                systemic inflammation defined by marked leukocytosis and elevated c-reactive&#xD;
                protein.&#xD;
&#xD;
        -  Both IL1RN and IL36RN/IL1F5 are highly expressed in epidermal keratinocytes, suggesting&#xD;
           a role for keratinocytes in initiating innate immunity-mediated inflammatory skin&#xD;
           diseases, and ultimately manifesting in a pustular phenotype.&#xD;
&#xD;
        -  Patients with inflammatory pustular diseases often respond poorly to conventional&#xD;
           treatment with methotrexate, cyclosporine and anti- tumor necrosis factor (TNF) agents.&#xD;
&#xD;
        -  Two recent case reports describe patients with pustular psoriasis unresponsive to TNF&#xD;
           inhibition who responded to anti-IL-1 receptor therapy with anakinra. We hypothesize&#xD;
           that monogenic and polygenic inflammatory pustular skin diseases share common pathogenic&#xD;
           mechanisms mediated by IL-1.&#xD;
&#xD;
        -  We propose a phase 2 study that will utilize a collaborative bench-to-bedside approach,&#xD;
           applying targeted anti-IL-1 therapy, novel imaging modalities, and laboratory techniques&#xD;
           including immunohistochemistry, gene expression and cytokine studies, and in vitro&#xD;
           manipulations of skin to dissect and validate pathways in these complex diseases.&#xD;
&#xD;
      Objectives:&#xD;
&#xD;
      -To characterize the clinical efficacy, optimal dosing and safety of anakinra in patients&#xD;
      with pustular dermatoses.&#xD;
&#xD;
      Eligibility:&#xD;
&#xD;
        -  Age greater than or equal to 18 years.&#xD;
&#xD;
        -  Active macroscopic noninfectious pustular skin lesions involving greater than or equal&#xD;
           to 5% of the total body surface area, or palmoplantar involvement.&#xD;
&#xD;
        -  Histopathologic confirmation of epidermal neutrophilic pustulosis.&#xD;
&#xD;
        -  Patients must have maintained a stable dose of immunosuppressant therapy, retinoids or&#xD;
           anti-neutrophil therapy for 2 weeks prior to study initiation with resultant stable or&#xD;
           worsening skin disease.&#xD;
&#xD;
        -  Use of biologic agents requires a washout period of at least 3 half-lives prior to study&#xD;
           initiation.&#xD;
&#xD;
        -  Patients must have organ and marrow function as defined below:&#xD;
&#xD;
             -  leukocytes &gt;3,000/mcL&#xD;
&#xD;
             -  absolute neutrophil count &gt;1,500/mcL&#xD;
&#xD;
             -  platelets &gt;100,000/mcL&#xD;
&#xD;
             -  creatinine within normal institutional limits OR creatinine clearance &gt;60&#xD;
                mL/min/1.73 m^2 for patients with creatinine levels above institutional normal.&#xD;
&#xD;
      Design:&#xD;
&#xD;
        -  A 16-week, open-label phase 2 study.&#xD;
&#xD;
        -  Patients will initially receive treatment with anakinra 100 mg/day by self-administered&#xD;
           subcutaneous injection.&#xD;
&#xD;
        -  Disease response will be assessed every 4 weeks, and determination of dose escalation&#xD;
           will be made based on clinical assessment. Dose escalation can increase up to 200&#xD;
           mg/day, and for patients &gt;75 kg up to 300 mg/day at the end of week 8.&#xD;
&#xD;
        -  If a response is achieved with anakinra, other immunosuppressants administered for the&#xD;
           purpose of treatment of pustular skin disease may be tapered per physician discretion.&#xD;
&#xD;
        -  Clinical assessment, and laboratory and subjective data will be collected in-person&#xD;
           every 4 weeks to determine disease response. Telephone assessments will be performed&#xD;
           weekly.&#xD;
&#xD;
        -  Twenty-five evaluable patients will be enrolled onto this trial. The accrual ceiling for&#xD;
           this study will be set to 30.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 22, 2013</start_date>
  <completion_date type="Actual">October 7, 2019</completion_date>
  <primary_completion_date type="Actual">March 19, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Treated With Anakinra Who Achieve 50% Disease Improvement by the End of Week 12, as Measured by Total Body Surface Area Involvement (TBSAI50)</measure>
    <time_frame>12 Weeks</time_frame>
    <description>Total Body Surface Area Involvement (TBSAI) is defined as the amount of total amount of active disease involvement on a given patient. 50% improvement was the amount of change that we judged at the start of the study would qualify as significant improvement.</description>
  </primary_outcome>
  <other_outcome>
    <measure>Number of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0)</measure>
    <time_frame>Up to 16 weeks for participants who completed active treatment (12 weeks) and 4 weeks of follow-up.</time_frame>
    <description>Here is the number of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned.</description>
  </other_outcome>
  <other_outcome>
    <measure>Average Change in Total Body Surface Area Index (TBSAI)</measure>
    <time_frame>Baseline and 12 Weeks</time_frame>
    <description>Median difference in affected area of plaque and pustular disease between baseline and week 12.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Sneddon-Wilkinson</condition>
  <condition>Acrodermatitis Continua of Hallopeau</condition>
  <condition>Pustular Psoriasis</condition>
  <condition>Palmoplantar Pustulosis</condition>
  <arm_group>
    <arm_group_label>Arm A/Anakinra 100 mg/day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>An initial dose of anakinra 100 mg/day will be administered daily via self-administered subcutaneous injection. If active disease persists at this dose, anakinra dose may be escalated up to 200 mg/day injected subcutaneously daily at week 4 and 300mg at week 8.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anakinra</intervention_name>
    <description>An initial dose of anakinra 100 mg/day will be administered daily via self-administered subcutaneous injection. If active disease persists at this dose, anakinra dose may be escalated up to 200 mg/day injected subcutaneously daily at week 4 and 300mg/day at week 8.</description>
    <arm_group_label>Arm A/Anakinra 100 mg/day</arm_group_label>
    <other_name>Kineret</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA&#xD;
&#xD;
        1.1 Females and males, aged greater than or equal to 18.&#xD;
&#xD;
        1.2 Patients must demonstrate active noninfectious inflammatory pustular skin lesions&#xD;
        resembling pustular psoriasis and involving greater than or equal to 5% total body surface&#xD;
        area, or palmoplantar involvement. Conditions may include, but are not be limited to,&#xD;
        pustular psoriasis, Sneddon-Wilkinson disease, subcorneal pustular dermatosis, reactive&#xD;
        arthritis, palmoplantar pustulosis, acrodermatitis continua of Hallopeau and palmoplantar&#xD;
        pustular psoriasis.&#xD;
&#xD;
        1.3 Patients must have histopathologic confirmation of epidermal neutrophilic pustular skin&#xD;
        disease.&#xD;
&#xD;
        1.4 If taking immunosuppressants, retinoids or anti-neutrophil therapy, participants must&#xD;
        maintain stable doses of these medications during the 2 weeks prior to study initiation.&#xD;
&#xD;
        1.5 Patients must have stable topical medication regimen for 2 weeks prior to study&#xD;
        initiation.&#xD;
&#xD;
        1.6 Patients must have normal organ and marrow function as defined below:&#xD;
&#xD;
        leukocytes greater than or equal to 3,000/mcL&#xD;
&#xD;
        absolute neutrophil count greater than or equal to1,500/mcL&#xD;
&#xD;
        platelets greater than or equal to 100,000/mcL&#xD;
&#xD;
        creatinine within normal institutional limits OR creatinine clearance greater than or equal&#xD;
        to 60 mL/min/1.73 m^2 for patients with creatinine levels above institutional normal.&#xD;
&#xD;
        1.7 Quantiferon tuberculosis (TB) Gold must be performed for screening for mycobacterium&#xD;
        tuberculosis infection. However, a tuberculin skin test may be placed if the Quantiferon TB&#xD;
        gold test is indeterminate. Patients must have a negative Quantiferon TB Gold (or&#xD;
        tuberculin skin test) or evidence of appropriate treatment prior to study entry.&#xD;
&#xD;
        1.8 Patients must be able to understand and sign a written informed consent document and&#xD;
        complete study-related procedures and questionnaires.&#xD;
&#xD;
        EXCLUSION CRITERIA&#xD;
&#xD;
        2.1 Enrollment in any other investigational treatment study or use of an investigational&#xD;
        agent, or has not yet completed at least 3 half-lives since ending another investigational&#xD;
        device or drug trial.&#xD;
&#xD;
        2.2 History of treatment with canakinumab within the 12 months prior to study initiation.&#xD;
&#xD;
        2.3 History of anakinra use.&#xD;
&#xD;
        2.4 History of phototherapy within 2 weeks prior to study initiation.&#xD;
&#xD;
        2.5 Patients may NOT concurrently be on biologic therapy such as etanercept, adalimumab,&#xD;
        alefacept, infliximab, rituximab or rilonacept. If there is a history of use of biologic&#xD;
        agents, there must be a washout period of at least 3 half-lives prior to study initiation.&#xD;
&#xD;
        2.6 Subjects who experience a significant flare after discontinuation of a tumor necrosis&#xD;
        factor (TNF) inhibitor as part of this study that requires urgent medical management or&#xD;
        hospitalization, or in the estimation of the principal investigator poses excessive risk to&#xD;
        the patient to enter the study.&#xD;
&#xD;
        2.7 Other defined dermatologic conditions which may include pustules as part of the&#xD;
        clinical presentation, but which clinically and/or histologically do not resemble pustular&#xD;
        psoriasis. Examples include, but are not limited to acute generalized exanthematous&#xD;
        pustulosis (Acute generalized exanthematous pustulosis (AGEP), a drug-induced pustular&#xD;
        dermatosis typically caused by beta-lactam antibiotics, tetracyclines, oral antifungals and&#xD;
        other drugs), bacterial or fungal folliculitis, cutaneous candidiasis, tinea pedis, tinea&#xD;
        corporis, neutrophilic eccrine hidradenitis or eosinophilic pustular folliculitis (Ofuji&#xD;
        syndrome).&#xD;
&#xD;
        2.8 Known diagnosis of Deficiency of the interleukin-1 receptor antagonist (DIRA).&#xD;
&#xD;
        2.9 History of allergic reactions attributed to compounds of similar chemical or biologic&#xD;
        composition to anakinra or other agents used in study. Known hypersensitivity to Chinese&#xD;
        hamster ovary (CHO)-cell derived biologics or any components of anakinra.&#xD;
&#xD;
        2.10 Treatment with a live virus vaccine during the 3 months prior to baseline visit. No&#xD;
        live vaccines will be allowed throughout the course of this study.&#xD;
&#xD;
        2.11 Patients with active or untreated malignancy-- with the exception of cutaneous basal&#xD;
        or squamous cell carcinomas, or in situ cervical carcinoma-- are ineligible because of the&#xD;
        immunomodulating effects of anakinra. The risk of recurrent malignancy secondary to this&#xD;
        drug is unknown.&#xD;
&#xD;
        2.12 Presence of active infection. History of exposure to TB (positive purified protein&#xD;
        derivative (PPD) or Quantiferon TB gold) who have not been treated with a TB prophylaxis&#xD;
        regimen for at least one month.&#xD;
&#xD;
        2.13 Chest x-ray demonstrating pleural scarring and/or calcified granuloma consistent with&#xD;
        prior or current untreated TB.&#xD;
&#xD;
        2.14 History of chronic or recurrent infection including but not limited to human&#xD;
        immunodeficiency virus (HIV), hepatitis B or hepatitis C.&#xD;
&#xD;
        2.15 Individuals with severe or uncontrolled recurrent cutaneous infections who are&#xD;
        considered at elevated risk for serious infection on anakinra therapy will be excluded per&#xD;
        physician discretion.&#xD;
&#xD;
        2.16 Presence of other known significant autoimmune or inflammatory disease. Examples&#xD;
        include major chronic infectious/inflammatory/immunologic diseases such as systemic lupus&#xD;
        erythematosus, rheumatoid arthritis, Sjogren's syndrome and periodic fever syndromes.&#xD;
&#xD;
        2.17 Other immunoregulatory or immunodeficiency diseases, such as multiple sclerosis.&#xD;
&#xD;
        2.18 Individuals with life-threatening or disabling inflammation of the eyes, gut or joints&#xD;
        requiring urgent or immediate medical attention, or at the physicians discretion.&#xD;
&#xD;
        2.19 Subjects for whom there is concern about compliance with the protocol procedures.&#xD;
&#xD;
        2.20 Uncontrolled intercurrent illness including, but not limited to, ongoing or active&#xD;
        infection, uncontrolled or unmonitored psychiatric illness/social situations, or history of&#xD;
        congestive heart failure, unstable angina pectoris or medically significant cardiac&#xD;
        arrhythmia that would limit compliance with study requirements.&#xD;
&#xD;
        2.21 Presence of other severe acute or chronic medical or psychiatric condition, or&#xD;
        significant laboratory abnormality requiring further investigation that may cause undue&#xD;
        risk for the subject's safety, inhibit protocol participation, or interfere with&#xD;
        interpretation of study results, and in the judgment of the investigator would make the&#xD;
        subject enrollment inappropriate.&#xD;
&#xD;
        2.22 The effects of anakinra on the developing human fetus are unknown. Women of&#xD;
        childbearing potential and men must agree to use adequate contraception (hormonal or&#xD;
        barrier method of birth control or abstinence) prior to study entry and for the duration of&#xD;
        study participation. Should a woman become pregnant or suspect she is pregnant while she or&#xD;
        her partner is participating in this study, she should inform her treating physician&#xD;
        immediately. Females of childbearing potential must have a negative serum pregnancy test at&#xD;
        screening. Females must also have a negative serum pregnancy test at baseline and prior to&#xD;
        performance of any radiologic procedure or administration of study medication and during&#xD;
        each National Institutes of Health (NIH) visit. Lactating mothers will discontinue&#xD;
        breastfeeding prior to study enrollment.&#xD;
&#xD;
        2.23 Pregnant or lactating females. Women of non-childbearing potential is defined as women&#xD;
        who are postmenopausal (no menses for &gt; one year) or who have had a hysterectomy and will&#xD;
        not require Beta-Human Chorionic Gonadotropin (B-HCG) testing&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>110 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Edward W Cowen, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center, 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://clinicalstudies.info.nih.gov/cgi/detail.cgi?B_2013-AR-0071.html</url>
    <description>NIH Clinical Center Detailed Web Page</description>
  </link>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>February 15, 2013</study_first_submitted>
  <study_first_submitted_qc>February 15, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 18, 2013</study_first_posted>
  <results_first_submitted>March 1, 2021</results_first_submitted>
  <results_first_submitted_qc>April 5, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">April 30, 2021</results_first_posted>
  <disposition_first_submitted>June 10, 2020</disposition_first_submitted>
  <disposition_first_submitted_qc>June 10, 2020</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">June 12, 2020</disposition_first_posted>
  <last_update_submitted>April 5, 2021</last_update_submitted>
  <last_update_submitted_qc>April 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)</investigator_affiliation>
    <investigator_full_name>Edward Cowen, M.D.</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Anakinra</keyword>
  <keyword>Pustular Psoriasis</keyword>
  <keyword>Palmoplantar Pustulosis</keyword>
  <keyword>DITRA</keyword>
  <keyword>Subcorneal Pustular Dermatosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acrodermatitis</mesh_term>
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interleukin 1 Receptor Antagonist Protein</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 12, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/17/NCT01794117/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>December 26, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/17/NCT01794117/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Week 4 Level 1 Only</title>
          <description>Anakinra Week 4 Level 1, 100mg administered subcutaneously daily.</description>
        </group>
        <group group_id="P2">
          <title>Week 4 Level 1 Followed by Week 8 Level 2</title>
          <description>Anakinra Week 4 Level 1, 100mg administered subcutaneously daily followed by Week 8 Level 2, 200 mg.</description>
        </group>
        <group group_id="P3">
          <title>Week 4 Level 1, Followed by Week 8 Level 2, Followed by Week 12 Level 2</title>
          <description>Anakinra Week 4 Level 1, 100mg administered subcutaneously daily followed by Week 8 Level 2, 200 mg, followed by Week 12 Level 2, 200mg.</description>
        </group>
        <group group_id="P4">
          <title>Week 4 Level 1, Followed by Week 8 Level 2, Followed by Week 12 Level 3</title>
          <description>Anakinra Week 4 Level 1, 100mg administered subcutaneously daily followed by Week 8 Level 2, 200 mg, followed by Week 12 Level 3, 300mg (participants 75kg only).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Participant noncompliance</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Refused further treatment</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Week 4 Level 1 Only</title>
          <description>Anakinra Week 4 Level 1, 100mg administered subcutaneously daily.</description>
        </group>
        <group group_id="B2">
          <title>Week 4 Level 1 Followed by Week 8 Level 2</title>
          <description>Anakinra Week 4 Level 1, 100mg administered subcutaneously daily followed by Week 8 Level 2, 200 mg.</description>
        </group>
        <group group_id="B3">
          <title>Week 4 Level 1, Followed by Week 8 Level 2, Followed by Week 12 Level 2</title>
          <description>Anakinra Week 4 Level 1, 100mg administered subcutaneously daily followed by Week 8 Level 2, 200 mg, followed by Week 12 Level 2, 200mg.</description>
        </group>
        <group group_id="B4">
          <title>Week 4 Level 1, Followed by Week 8 Level 2, Followed by Week 12 Level 3</title>
          <description>Anakinra Week 4 Level 1, 100mg administered subcutaneously daily followed by Week 8 Level 2, 200 mg, followed by Week 12 Level 3, 300mg (participants 75kg only).</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1"/>
            <count group_id="B2" value="3"/>
            <count group_id="B3" value="2"/>
            <count group_id="B4" value="12"/>
            <count group_id="B5" value="18"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49.0" spread="0"/>
                    <measurement group_id="B2" value="45.43" spread="1.51"/>
                    <measurement group_id="B3" value="49.9" spread="20.51"/>
                    <measurement group_id="B4" value="51.55" spread="11.53"/>
                    <measurement group_id="B5" value="50.21" spread="10.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="12"/>
                    <measurement group_id="B5" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="12"/>
                    <measurement group_id="B5" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Treated With Anakinra Who Achieve 50% Disease Improvement by the End of Week 12, as Measured by Total Body Surface Area Involvement (TBSAI50)</title>
        <description>Total Body Surface Area Involvement (TBSAI) is defined as the amount of total amount of active disease involvement on a given patient. 50% improvement was the amount of change that we judged at the start of the study would qualify as significant improvement.</description>
        <time_frame>12 Weeks</time_frame>
        <population>14/18 were analyzed because 4 pts did not meet the study primary endpoint (stayed on treatment until 12 wks). The study was not powered nor intended to study/compare differences between dose levels. The dose escalation was done for safety purposes rather than dose finding.</population>
        <group_list>
          <group group_id="O1">
            <title>All Participants</title>
            <description>All participants that received Anakinra 100mg, 200mg, and 300mg administered subcutaneously daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Treated With Anakinra Who Achieve 50% Disease Improvement by the End of Week 12, as Measured by Total Body Surface Area Involvement (TBSAI50)</title>
          <description>Total Body Surface Area Involvement (TBSAI) is defined as the amount of total amount of active disease involvement on a given patient. 50% improvement was the amount of change that we judged at the start of the study would qualify as significant improvement.</description>
          <population>14/18 were analyzed because 4 pts did not meet the study primary endpoint (stayed on treatment until 12 wks). The study was not powered nor intended to study/compare differences between dose levels. The dose escalation was done for safety purposes rather than dose finding.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0)</title>
        <description>Here is the number of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned.</description>
        <time_frame>Up to 16 weeks for participants who completed active treatment (12 weeks) and 4 weeks of follow-up.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Week 4 Level 1 Only</title>
            <description>Anakinra Week 4 Level 1, 100mg administered subcutaneously daily.</description>
          </group>
          <group group_id="O2">
            <title>Week 4 Level 1 Followed by Week 8 Level 2</title>
            <description>Anakinra Week 4 Level 1, 100mg administered subcutaneously daily followed by Week 8 Level 2, 200 mg.</description>
          </group>
          <group group_id="O3">
            <title>Week 4 Level 1, Followed by Week 8 Level 2, Followed by Week 12 Level 2</title>
            <description>Anakinra Week 4 Level 1, 100mg administered subcutaneously daily followed by Week 8 Level 2, 200 mg, followed by Week 12 Level 2, 200mg.</description>
          </group>
          <group group_id="O4">
            <title>Week 4 Level 1, Followed by Week 8 Level 2, Followed by Week 12 Level 3</title>
            <description>Anakinra Week 4 Level 1, 100mg administered subcutaneously daily followed by Week 8 Level 2, 200 mg, followed by Week 12 Level 3, 300mg (participants 75kg only).</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0)</title>
          <description>Here is the number of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life-threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="2"/>
                <count group_id="O4" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Average Change in Total Body Surface Area Index (TBSAI)</title>
        <description>Median difference in affected area of plaque and pustular disease between baseline and week 12.</description>
        <time_frame>Baseline and 12 Weeks</time_frame>
        <population>The study was not powered nor intended to study/compare differences between dose levels. The dose escalation was done for safety purposes rather than dose finding.</population>
        <group_list>
          <group group_id="O1">
            <title>All Participants</title>
            <description>All participants that received Anakinra 100mg, 200mg, and 300mg administered subcutaneously daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Average Change in Total Body Surface Area Index (TBSAI)</title>
          <description>Median difference in affected area of plaque and pustular disease between baseline and week 12.</description>
          <population>The study was not powered nor intended to study/compare differences between dose levels. The dose escalation was done for safety purposes rather than dose finding.</population>
          <units>Percentage of total skin involvement</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.9" lower_limit="-1.8" upper_limit="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.033</p_value>
            <method>Wilcoxon Signed Rank Test</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 16 weeks for participants who completed active treatment (12 weeks) and 4 weeks of follow-up.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Week 4 Level 1 Only</title>
          <description>Anakinra Week 4 Level 1, 100mg administered subcutaneously daily.</description>
        </group>
        <group group_id="E2">
          <title>Week 4 Level 1 Followed by Week 8 Level 2</title>
          <description>Anakinra Week 4 Level 1, 100mg administered subcutaneously daily followed by Week 8 Level 2, 200 mg.</description>
        </group>
        <group group_id="E3">
          <title>Week 4 Level 1, Followed by Week 8 Level 2, Followed by Week 12 Level 2</title>
          <description>Anakinra Week 4 Level 1, 100mg administered subcutaneously daily followed by Week 8 Level 2, 200 mg, followed by Week 12 Level 2, 200mg.</description>
        </group>
        <group group_id="E4">
          <title>Week 4 Level 1, Followed by Week 8 Level 2, Followed by Week 12 Level 3</title>
          <description>Anakinra Week 4 Level 1, 100mg administered subcutaneously daily followed by Week 8 Level 2, 200 mg, followed by Week 12 Level 3, 300mg (participants 75kg only).</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin and subcutaneous tissue disorders - Other, Flare of Pustular Psoriasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="2"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye disorders - Other, (Stye L eye)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="3" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Eye disorders - Other, (Stye R eye)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="4" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E4" events="9" subjects_affected="6" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Oral hemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Rectal hemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="2"/>
                <counts group_id="E4" events="10" subjects_affected="9" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="8" subjects_affected="4" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Edema limbs</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="4" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Localized edema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Portal vein thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infections and infestations - Other, L foot infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Upper respiratory infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Vaginal infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Bruising</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Alkaline phosphatase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Cholesterol high</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Creatinine increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>GGT increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Lymphocyte count decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoalbuminemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Hypernatremia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Hyperuricemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Hypocalcemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Hypertriglyceridemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="4" subjects_affected="3" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="4" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="31" subjects_affected="7" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Paresthesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory, thoracic and mediastinal disorders - Other, Running Nose</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Allergic rhinitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Sinus pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="8" subjects_affected="3" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Pain of skin</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="6" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Papulopustular rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="12" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Rash acneiform</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Skin and subcutaneous tissue disorders - Other, Hiradenitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E4" events="4" subjects_affected="3" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Edward W. Cowen</name_or_title>
      <organization>National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)</organization>
      <phone>301-827-2328</phone>
      <email>cowene@mail.nih.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

